Explore the latest news and publications from Latigo Biotherapeutics
Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins…
Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial Fast…
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience Walbert led…
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
Potential best-in-class non-opioid Nav1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by…
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
Former William Blair partner and group head, Lugo has facilitated raising more than $6 billion…
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer
Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to…
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
Farzan brings more than two decades’ leadership experience with a strong track record in fundraising…